- Home
- MYGN vs ARCB Comparison
MYGN vs ARCB Comparison
Compare MYGN & ARCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- ARCB
- Stock Information
- Founded
- MYGN 1991
- ARCB 1923
- Country
- MYGN United States
- ARCB United States
- Employees
- MYGN N/A
- ARCB N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ARCB Trucking Freight/Courier Services
- Sector
- MYGN Health Care
- ARCB Industrials
- Exchange
- MYGN Nasdaq
- ARCB Nasdaq
- Market Cap
- MYGN 2.0B
- ARCB 2.6B
- IPO Year
- MYGN 1995
- ARCB N/A
- Fundamental
- Price
- MYGN $13.36
- ARCB $94.13
- Analyst Decision
- MYGN Hold
- ARCB Buy
- Analyst Count
- MYGN 12
- ARCB 14
- Target Price
- MYGN $23.92
- ARCB $130.69
- AVG Volume (30 Days)
- MYGN 942.4K
- ARCB 230.2K
- Earning Date
- MYGN 11-07-2024
- ARCB 02-04-2025
- Dividend Yield
- MYGN N/A
- ARCB 0.51%
- EPS Growth
- MYGN N/A
- ARCB 8.96
- EPS
- MYGN N/A
- ARCB 8.07
- Revenue
- MYGN $823,600,000.00
- ARCB $4,266,908,999.00
- Revenue This Year
- MYGN $13.82
- ARCB N/A
- Revenue Next Year
- MYGN $4.59
- ARCB $4.21
- P/E Ratio
- MYGN N/A
- ARCB $11.67
- Revenue Growth
- MYGN 12.15
- ARCB N/A
- 52 Week Low
- MYGN $12.87
- ARCB $92.59
- 52 Week High
- MYGN $29.30
- ARCB $153.60
- Technical
- Relative Strength Index (RSI)
- MYGN 26.22
- ARCB 28.10
- Support Level
- MYGN $12.87
- ARCB $104.28
- Resistance Level
- MYGN $15.44
- ARCB $113.74
- Average True Range (ATR)
- MYGN 0.84
- ARCB 3.86
- MACD
- MYGN -0.02
- ARCB -1.78
- Stochastic Oscillator
- MYGN 12.37
- ARCB 7.28
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About ARCB ArcBest Corporation
ArcBest Corp is engaged in logistics operations. The company operates in two operating segments, The Asset-Based segment includes the results of operations of ABF Freight System, Inc. and certain other subsidiaries. The segment operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed LTL services. The services including freight transportation related to managed transportation solutions and other services. The Asset-Light segment includes the results of operations of the Company's service offerings in truckload, ground expedite, dedicated, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.